drugset / Trial / NCT02385097

Chloroprocaine 2% vs Ropivacaine 0.75% in Ultrasound-guided Axillary Nerve Block

NCT02385097

Phase 3 Completed 211 enrolled Sintetica SA Cross S.A. · collab
RandomizedParallel-groupTriple-blindOther

Summary

The Study evaluate the non-inferiority of Test product (Chloroprocaine 2%) versus Reference product (Ropivacaine 0.75%) in terms of proportion of subjects with a successful block for distal upper limb surgeries Successful block: anaesthesia adequate for the surgery without any supplementation in the first 45 min.

Timeline

Start
2015-04
Primary completion
2017-05
Completion
2017-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Chloroprocaine Other / unclassified 20 ml Other
Comparator Ropivacaine Other / unclassified 20 ml Other

Indications

No indication recorded.